May 13, 2014 8:00 a.m. to 6:00 p.m.: Ophthalmic Devices Panel of the Medical Devices Advisory Committee Meeting Announcement.
May 13, 2014 8:00 a.m. to 6:00 p.m.: Ophthalmic Devices Panel of the Medical Devices Advisory Committee Meeting Announcement
Holiday Inn Express/Highlands Conference Center
Oak I and II Conference Rooms
20260 Goldenrod Lane
Germantown, MD 20876
At this meeting, the Ophthalmic Devices Panel of the Medical Devices Advisory Committee will discuss and make recommendations regarding the guidance documents for contact lenses and contact lens accessories. The discussion will include topics such as microbiological and chemical pre-clinical testing, revision of pre-clinical test requirements to address patient non-compliance, modification of rigid gas permeable lens care regimens, and labeling for these devices.
The current guidance for contact lenses entitled “Premarket Notification [510(k)] Guidance Document for Class II Daily Wear Contact Lenses” and can be found here.
The current guidance for contact lens accessories entitled “Premarket Notification [510(k)] Guidance Document for Contact Lens Care Products” and can be found here.
Please click here for the current roster of the Ophthalmic Devices Panel of the Medical Devices Advisory Committee
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us